Abstract: The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further relates to methods that can be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting NGF-trk receptor pairs and the phosphorylation of trk protein.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 22, 1998
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: The invention involves the purification of various glial mitogenic factors. In one aspect of the invention, vertebrate brain material is extracted, and the extract is then subjected to chromatographic separation. The glial mitogenic factors which can be obtained include a basic polypeptide with a molecular weight of from about 30 to about 36 kD, by reference to SDS-PAGE, and a second basic polypeptide factor which is from about 55 to about 63 kD as determined by SDS-page.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
February 25, 1997
Assignees:
Ludwig Institute for Cancer Research, Cambridge Neuroscience
Inventors:
Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario S. Chen, Ian Hiles
Abstract: Method for the recovery and purification of intact, correctly-folded, monomeric insulin-like growth factor-1 peptide from large volumes of IGF-1-containing medium are described, comprising a series of adsorption-desorption steps employing a combination of cation exchange and hydrophobic interaction adsorbents. Product IGF-1 peptide is highly purified and suitable for use in a variety of clinical applications.
Type:
Grant
Filed:
October 28, 1991
Date of Patent:
July 27, 1993
Assignee:
The Salk Institute Biotechnology/Industrial Associates, Inc.
© 2024 Justia
